Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENTANYL vs ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a synthetic opioid that primarily acts as a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system (CNS), leading to G-protein-coupled receptor activation, inhibition of adenylate cyclase, decreased c AMP production, and modulation of ion channels (e.g., increased potassium efflux, decreased calcium influx). This results in hyperpolarization of neurons and reduced neurotransmitter release, producing analgesia, sedation, and euphoria. Fentanyl also has high lipid solubility, allowing rapid CNS penetration and a fast onset of action.
Acetaminophen: cyclooxygenase (COX) inhibitor, primarily in the CNS, reducing prostaglandin synthesis; analgesic and antipyretic. Oxycodone: mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception.
Anesthesia adjunct (induction and maintenance),Analgesia during anesthesia (e.g., for surgery, mechanical ventilation),Management of acute pain (e.g., procedural sedation),Treatment of breakthrough pain in opioid-tolerant patients (via transmucosal formulations),Patient-controlled analgesia (PCA),Epidural or intrathecal analgesia (off-label),Prehospital analgesia for trauma (off-label)
Management of moderate to moderately severe pain,Acute pain,Chronic pain
25-100 mcg IV every 1-2 hours as needed; 50-100 mcg IM every 1-2 hours; transdermal patch: 12.5-100 mcg/h every 72 hours; transmucosal: 200-1600 mcg as single dose.
1-2 tablets (equivalent to 325-650 mg acetaminophen / 5-10 mg oxycodone) every 4-6 hours as needed for pain; maximum 12 tablets per day (acetaminophen limit 3900 mg/day or lower if hepatic risk).
Terminal elimination half-life is 3–12 hours (mean ~7 hours) in adults; prolonged in elderly, hepatic impairment, or with continuous infusion due to context-sensitive half-life.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment or overdose); Oxycodone: 3-5 hours (immediate-release), 4.5-8 hours (extended-release); Clinical context: Terminal half-life of oxycodone may be prolonged in elderly or patients with renal/hepatic impairment.
Fentanyl undergoes extensive hepatic metabolism primarily via CYP3A4 N-dealkylation to norfentanyl (inactive) and other minor metabolites. Approximately 75% of the dose is excreted as metabolites in urine (primarily norfentanyl) and about 9% in feces. Less than 7% is excreted unchanged in urine. The terminal half-life is 3–12 hours, influenced by factors such as hepatic function and age.
Acetaminophen: primarily hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1), and minor CYP450 (CYP2E1, CYP3A4) to toxic NAPQI. Oxycodone: hepatic via CYP3A4 (major) and CYP2D6 (minor) to active metabolites (noroxycodone, oxymorphone).
Primarily hepatic metabolism to norfentanyl and other inactive metabolites; renal excretion of metabolites accounts for ~75% of the dose (10% unchanged), with ~9% excreted in feces.
Acetaminophen: renal excretion of metabolites (glucuronide 45-55%, sulfate 20-30%, cysteine and mercapturate conjugates 5-10%) and unchanged drug (<5%); Oxycodone: renal excretion of unchanged drug (approximately 10-19%) and metabolites (noroxycodone, oxymorphone, and their glucuronides) (total renal elimination ~60-87%); fecal elimination of Oxycodone is minimal (<10%).
~80–85% bound primarily to albumin and alpha-1-acid glycoprotein.
Acetaminophen: 20-30% (albumin); Oxycodone: 45-50% (albumin).
Vd: 3–8 L/kg (mean ~4 L/kg), indicating extensive tissue distribution and high lipophilicity.
Acetaminophen: 0.9-1.0 L/kg (suggests distribution into total body water); Oxycodone: 2.6-4.0 L/kg (suggests extensive tissue distribution).
Transdermal: ~92%; Transmucosal (buccal): ~50%; Oral transmucosal lozenge: ~33%; Intranasal: ~50–70%; Oral (swallowed): very low due to first-pass metabolism (~30% but variable).
Acetaminophen: Oral 85-90%; Oxycodone: Oral 60-87% (first-pass metabolism), Rectal (oxycodone suppository) ~60-80%.
GFR 30-50: use with caution, consider dose reduction by 25-50%; GFR <30: avoid or initiate at 50% of usual dose and titrate slowly; anuric patients: significant accumulation, consider alternative.
e GFR 30-60 m L/min: start with 50% of usual dose, increase cautiously; e GFR <30 m L/min: start with 25% of usual dose, extend dosing interval to every 8-12 hours; avoid in dialysis due to oxycodone accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or use with extreme caution, reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: start with 50% of usual dose, maximum acetaminophen 2000 mg/day; Child-Pugh C: contraindicated.
IV: 1-2 mcg/kg every 2-4 hours; transdermal: not recommended in opioid-naïve children <2 years, start at 12.5 mcg/h if >50 kg; transmucosal: 5-15 mcg/kg as single dose.
Weight-based: oxycodone 0.05-0.15 mg/kg/dose (max 5 mg/dose) with acetaminophen 10-15 mg/kg/dose every 4-6 hours; maximum acetaminophen 75 mg/kg/day (not to exceed 4000 mg/day).
Start at 50% of usual adult dose, titrate cautiously by 25% increments; avoid transdermal in opioid-naïve elderly; monitor for respiratory depression and cognitive impairment.
Start with lowest dose (e.g., half of adult dose), titrate slowly; avoid in patients with impaired renal/hepatic function or those at risk for falls; monitor for respiratory depression and constipation.
WARNING: RISK OF RESPIRATORY DEPRESSION, ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTION WITH ALCOHOL; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISK OF MEDICATION ERRORS (especially with transmucosal formulations).
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen may cause hepatotoxicity; neonatal opioid withdrawal syndrome; CYP3A4 interaction with benzodiazepines or other CNS depressants.
Life-threatening respiratory depression: risk dose-dependent; monitor respiratory function, especially during initiation and dose escalation.,Addiction, abuse, and misuse: can occur even at recommended doses; screen patients for risk.,Neonatal opioid withdrawal syndrome: prolonged use during pregnancy can result in withdrawal in the newborn.,Interaction with CNS depressants: concomitant use with benzodiazepines or alcohol may cause profound sedation, respiratory depression, coma, and death.,Accidental exposure: especially with transdermal patches; can be fatal.,Risks from use in patients with head injury or increased intracranial pressure: may obscure neurological signs.,Severe hypotension: in patients with compromised blood volume or concomitant use of drugs that depress blood pressure.,Bradycardia and heart block: use with caution in patients with bradyarrhythmias.,Seizures: may exacerbate seizure disorders.,Serotonin syndrome: when used with serotonergic drugs.,Adrenal insufficiency: with prolonged use.,Severe injection site reactions: with injectable formulations.,Risk of medication errors: especially with different formulations (e.g., transdermal vs. transmucosal).
Addiction, abuse, misuse; respiratory depression; accidental exposure; neonatal opioid withdrawal syndrome; hepatotoxicity (acetaminophen); interactions with CNS depressants; elderly or debilitated patients; renal impairment; severe hypotension; adrenal insufficiency; use in patients with head injury.
Hypersensitivity to fentanyl or any component of the formulation,Significant respiratory depression (in unmonitored settings or without resuscitative equipment),Acute or severe bronchial asthma,Paralytic ileus (known or suspected),Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy,Use in opioid-naive patients for transmucosal immediate-release fentanyl (due to risk of fatal respiratory depression),Acute abdomen (relative contraindication; may obscure diagnosis)
Hypersensitivity to acetaminophen or oxycodone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction (e.g., paralytic ileus); severe hepatic impairment; concurrent use with MAOIs or within 14 days.
Avoid grapefruit and grapefruit juice as they can increase fentanyl levels via CYP3A4 inhibition. No other significant food interactions. Maintain adequate hydration to prevent constipation.
Avoid alcohol. Grapefruit juice may increase oxycodone levels; limit or avoid grapefruit products. High-fat meals may delay absorption of oxycodone. Maintain adequate hydration to prevent constipation.
First trimester: Limited data; no major malformations reported. Second and third trimesters: Chronic maternal use may lead to neonatal opioid withdrawal syndrome. High doses near term may cause respiratory depression and neonatal abstinence syndrome.
Acetaminophen: Generally considered low risk; no consistent association with major malformations. Oxycodone: First trimester: No increased risk of major malformations in human studies. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use; respiratory depression at delivery. No specific human data for combination; extrapolated from individual components.
Fentanyl is excreted into breast milk. Milk-to-plasma ratio is approximately 0.4. Avoid use in lactating women who are poor metabolizers or receive high doses due to risk of infant sedation and respiratory depression.
Acetaminophen: Compatible; M/P ratio ~1.0 (low transfer). Oxycodone: Low levels in milk; M/P ratio ~3.6 (relative infant dose 1.7–6.3% of maternal weight-adjusted dose). Monitor infant for drowsiness, respiratory depression. Use lowest effective dose, shortest duration.
Clearance of fentanyl is increased during pregnancy, particularly in the third trimester. Dose adjustments may be required; consider increasing dose or frequency. Monitor for efficacy and adjust as needed.
Acetaminophen: No dose adjustment needed; use lowest effective dose. Oxycodone: Pharmacokinetic changes in pregnancy include increased clearance (due to enhanced hepatic metabolism and renal blood flow) and increased volume of distribution, potentially reducing plasma concentrations. Dose may need to be increased (monitor for efficacy and avoid withdrawal); however, use lowest effective dose to minimize neonatal risks. Consider non-opioid alternatives.
Fentanyl is 50-100 times more potent than morphine. Due to high lipophilicity, onset of analgesia is rapid (within 30 seconds IV) but duration is short. Avoid bolus dosing in opioid-naive patients due to risk of chest wall rigidity. Transdermal patches are not indicated for acute pain due to slow onset and prolonged effect. Monitor for respiratory depression, especially in elderly and those with sleep apnea. Tolerance and physical dependence develop with chronic use. Naloxone is the reversal agent.
Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen intake should not exceed 4000 mg. Oxycodone has high abuse potential; consider prescribing naloxone for patients at risk of opioid overdose. Avoid concurrent use of other CNS depressants. Use with caution in elderly or renally impaired patients.
Do not drive or operate heavy machinery until you know how fentanyl affects you.,Take exactly as prescribed; do not increase dose or frequency without doctor approval.,Avoid alcohol and other CNS depressants as they increase risk of severe drowsiness and respiratory depression.,Store fentanyl patches and other formulations safely out of reach of children and pets; used patches should be folded and flushed down toilet.,Do not share this medication with others; it can cause fatal overdose.,Seek emergency medical help if you experience slow/shallow breathing, extreme drowsiness, or difficulty waking up.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.
Do not exceed 4000 mg of acetaminophen per day from all sources.,This medication can cause drowsiness; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol while taking this medication.,Take exactly as prescribed; do not crush, chew, or break extended-release tablets.,Store securely out of reach of children and dispose of unused medication properly.,Seek emergency medical attention if you experience difficulty breathing, severe drowsiness, or signs of an allergic reaction.
"Metaraminol, a direct-acting alpha-adrenergic agonist, can reduce the serum concentration of fentanyl, a potent opioid analgesic, likely through enhanced hepatic metabolism or altered renal clearance. This interaction may lead to diminished analgesic efficacy of fentanyl, requiring higher doses to achieve pain control and potentially increasing the risk of opioid withdrawal symptoms. Clinically, patients receiving both drugs may exhibit inadequate pain relief or unexpected opioid tolerance."
"The concomitant use of pergolide, a dopamine receptor agonist, and fentanyl, a μ-opioid receptor agonist, may result in additive central nervous system depression, leading to increased sedation, respiratory depression, and potential for coma or death. Pergolide can also potentiate the hypotensive effects of opioids, resulting in orthostatic hypotension and syncope. Additionally, both drugs can prolong the QTc interval, increasing the risk of torsades de pointes and sudden cardiac death."
"The combination of glycopyrronium, an anticholinergic agent, and fentanyl, a potent mu-opioid receptor agonist, can result in additive anticholinergic effects, specifically severe constipation, urinary retention, and central nervous system depression, leading to delirium or cognitive impairment in susceptible patients. Additionally, fentanyl-induced gastrointestinal hypomotility is exacerbated by glycopyrronium, increasing the risk of paralytic ileus. Clinically, patients may present with prolonged QTc interval, decreased gastrointestinal motility, and exacerbated sedation, particularly in elderly or renally impaired individuals."
"Phenobarbital, a potent inducer of cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2D6, significantly increases the hepatic metabolism of oxycodone, a prodrug that requires CYP3A4-mediated N-demethylation to noroxycodone and CYP2D6-mediated O-demethylation to oxymorphone for its analgesic effects. This induction reduces the systemic exposure and peak plasma concentration of active oxycodone and its active metabolite oxymorphone, leading to diminished analgesic efficacy and potential opioid withdrawal symptoms in patients on chronic opioid therapy. Clinically, patients may require substantially higher doses of oxycodone to achieve pain relief, increasing the risk of dose-related adverse effects if the interaction is not recognized."
"The co-administration of oxycodone, a mu-opioid receptor agonist, and gamma-hydroxybutyric acid (GHB), a central nervous system depressant with activity at GABA-B and GHB receptors, results in additive or synergistic respiratory depression and CNS depression. This interaction potentiates the risk of severe hypoventilation, coma, and fatal overdose, especially in non-tolerant users or at therapeutic doses. The combined sedation also increases the likelihood of hypotension, bradycardia, and impaired psychomotor function, necessitating extreme caution."
"The coadministration of oxycodone, a mu-opioid receptor agonist with central nervous system (CNS) depressant effects, and perampanel, a noncompetitive AMPA receptor antagonist that also causes CNS depression, produces additive sedative and respiratory depressant effects. This synergy increases the risk of excessive sedation, impaired cognitive function, and potentially life-threatening respiratory depression. Patients may experience profound somnolence, confusion, and an increased fall risk, necessitating dose adjustments or avoidance."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENTANYL vs ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE, answered by our medical review team.
FENTANYL is a Opioid Agonist that works by Fentanyl is a synthetic opioid that primarily acts as a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system (CNS), leading to G-protein-coupled receptor activation, inhibition of adenylate cyclase, decreased c AMP production, and modulation of ion channels (e.g., increased potassium efflux, decreased calcium influx). This results in hyperpolarization of neurons and reduced neurotransmitter release, producing analgesia, sedation, and euphoria. Fentanyl also has high lipid solubility, allowing rapid CNS penetration and a fast onset of action.. ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is a Opioid Agonist that works by Acetaminophen: cyclooxygenase (COX) inhibitor, primarily in the CNS, reducing prostaglandin synthesis; analgesic and antipyretic. Oxycodone: mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENTANYL and ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENTANYL is: 25-100 mcg IV every 1-2 hours as needed; 50-100 mcg IM every 1-2 hours; transdermal patch: 12.5-100 mcg/h every 72 hours; transmucosal: 200-1600 mcg as single dose.. The standard adult dose of ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is: 1-2 tablets (equivalent to 325-650 mg acetaminophen / 5-10 mg oxycodone) every 4-6 hours as needed for pain; maximum 12 tablets per day (acetaminophen limit 3900 mg/day or lower if hepatic risk).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining FENTANYL and ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE. The risk or severity of adverse effects can be increased when Oxycodone is combined with Fentanyl. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. FENTANYL is classified as Category D/X. First trimester: Limited data; no major malformations reported. Second and third trimesters: Chronic maternal use may lead to neonatal opioid withdrawal syndrome. High doses near t. ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent association with major malformations. Oxycodone: First trimester: No increased risk of major malformations in human stud. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.